A new Case Study is available, sponsored by Evotec. The study of health and disease through multi-omics research generates vast amounts of interconnected data. Unlocking their secrets requires complex bioinformatic exploration. This analysis is accelerated by a dedicated and flexible software application that is not only reliable and provides… Read More
The study of health and disease through multi-omics research generates vast amounts of interconnected data. Unlocking their secrets requires complex bioinformatic exploration. This analysis is accelerated by a dedicated and flexible software application that is not only reliable and provides reproducible results, but also facilitates collaboration between project investigators… Read More
Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More
Hosted by DDW and sponsored by DNA Script, watch this free roundtable on demand to learn about the biggest opportunities for the future of drug discovery and development. Roundtable panellists include Commercial Research Scientist, Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel… Read More
The latest eBook by DDW is out now. This 28-page eBook, sponsored by Benchling, examines the ways in which artificial intelligence and machine learning are expediting drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence… Read More
This latest eBook sponsored by Benchling features insight on how artificial intelligence is helping advance drug discovery efforts. Download this exclusive eBook to learn more about: The latest advancements in artificial intelligence How machine learning is being used across cancer research Why AI is critical to solving challenges in drug… Read More
Eli Lilly and XtalPi have entered an AI drug discovery collaboration of up to $250 million in upfront and milestone payments. XtalPi is a pharmaceutical technology company with operations in China and the US. The collaboration will use XtalPi’s integrated AI and robotics platform… Read More
This article is sponsored by Benchling. “What’s the single most important factor when building a machine learning model? Data! Having the right data, and an understanding of the uncertainty in that data often makes the difference between useful and useless models,” said Pat Walters, Chief Data… Read More
PharmEnable has closed a pre-series A investment round of $7.5 million to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi Tanabe Pharma Group. There was also participation… Read More
A molecular machine, which plays an essential ‘cargo’ role in controlling the delivery of proteins to the surface of human cells has been identified using artificial intelligence (AI). The research has shown how manipulating this process could treat or prevent disease, with implications for SARS-CoV-2, human… Read More
Listen to this article on the DDW Podcast: Professor Sonika Bhatnagar explores how artificial intelligence is enabling drug discovery at rates never seen before. A bullet for cure The year was 1907, and Paul Ehrlich, the German Nobel laureate had proposed the idea of a magic bullet to cure diseases. The magic… Read More
Listen to this article on the DDW Podcast: Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within… Read More
An investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant recurrence in patients with endometrial cancer, according to findings presented at the AACR Annual Meeting 2023. Endometrial cancer is the most common type of uterine cancer. While patients with early-stage uterine… Read More
Endogena Therapeutics has completed the dose-escalation stage of its Phase I/IIa study of EA-2353 in retinitis pigmentosa (RP) with no clinically relevant or dose-limiting adverse events. Given the positive safety and tolerability profile, the study will now enrol patients into the expansion cohort, using the highest… Read More
US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Diana Spencer spoke to Raphael Townshend, PhD, Founder and CEO of Atomic AI, about the advantages of combining two such exciting technologies. Artificial Intelligence (AI) has been enthusiastically adopted by the drug discovery… Read More
Iktos has raised €15.5m in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions. The round was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. The financing will enable the company to launch Iktos Robotics; a drug… Read More
